Our mission is to contain rapidly evolving viruses with vaccines that activate both branches of the immune system.
Transmucosis has built the only protein-based vaccination platform that will activate both mucosal and systemic branches of the immune system.
We believe that dual immune activation will be required to contain rapidly evolving viruses like SARS-CoV-2, and other pathogens including Influenza and RSV.
Transmucosis is exploiting the unique properties of the FcRn receptor to actively transport its vaccine molecules across epithelial cell barriers.
The challenge for current vaccines is to keep pace with the rapidly evolving SARS-CoV-2 virus. Transmucosis offers a promising solution to contain COVID-19 by combining multiple variant antigens in a single vaccine molecule.